

# Development of a Quantitative UPLC/MS/MS Assay for the Simultaneous Quantification of Acetylcholine, Histamine, and their Metabolites in Human Cerebrospinal Fluid (CSF) Using a CORTECS UPLC HILIC Column to Improve Peak Resolution, Sensitivity, and Speed of Analysis

Mary E. Lame, Erin E. Chambers, and Kenneth J. Fountain  
 Waters Corporation, Milford, MA, USA

## APPLICATION BENEFITS

- Resolution of the CORTECS™ UPLC® HILIC Column provides simultaneous quantification of ACh, HA, and their metabolites
- Total run time of 2.5 minutes meets high throughput screening demands
- Simple sample preparation (<15 minutes) in a 96-well format
- High sensitivity achieved with the Xevo® TQ-S MS facilitates use of smaller sample volumes and higher dilution volumes than previously reported

## WATERS SOLUTIONS

ACQUITY UPLC® System

Xevo TQ-S Mass Spectrometer

CORTECS UPLC HILIC Column

ACQUITY® Collection Plate

## KEY WORDS

Bioanalysis, biomarkers, cerebrospinal fluid, quantification, neurotransmitters, acetylcholine, choline, histamine, *tele*-Methylhistamine, *tele*-Methylimidazoleacetic acid, UPLC, HILIC, CORTECS

## INTRODUCTION



[Meet the scientist behind the application and hear a short summary of her work.\\*](#)

Biochemical biomarkers, derived from bodily fluids, are often employed in drug discovery and development as a useful way of identifying disease or effectiveness of drug treatment. Acetylcholine (ACh) and Histamine (HA) are highly polar neurotransmitters and are present in almost all mammalian tissues. They play a role in sleep

regulation, memory and learning, and immune responses.<sup>1-3</sup> A decrease in ACh levels in the brain is a known contributor to memory dysfunction, and is in particularly short supply in people with Alzheimer's Disease.<sup>1</sup> Thus, increased release of ACh is extensively researched in treatments of these cognitive disorders.

Histamine is derived from the decarboxylation of the amino acid, histidine. Histamine is either stored or rapidly inactivated by its primary degradative enzymes, histamine-N-methyltransferase, or diamine oxidase, and metabolized to two major metabolites, *tele*-Methylhistamine (t-mHA) and *tele*-methylimidazoleacetic acid (t-MIAA). Brain histamine is involved in a wide range of physiological functions, such as regulation of sleep-wake cycle, arousal, appetite control, cognition, learning, and memory.<sup>2,3</sup> It is known that metabolites




Figure 1. Structures of ACh, HA, and their respective metabolites.

of histamine are increased in the cerebrospinal fluid of people with schizophrenia.<sup>4,5</sup> Thus, the concentrations of HA, t-mHA, and t-MIAA in CSF could be used as indicators of brain histaminergic activity. Given the physiological importance of both ACh as well as HA and their metabolites, the ability to measure changes in their physiological concentrations as a function of disease progression or drug treatment make them of great interest as biochemical biomarkers in drug discovery and development.

The development of targeted assays for ACh, HA and their respective metabolites, is a persistent challenge due to the demand for high sensitivity, selectivity, and fast sample analysis times. Additionally, simultaneous measurement requires a broad quantitative dynamic range due to the vast difference in endogenous circulating concentrations between ACh, HA, and their metabolites. While there are a number of analytical methodologies for quantifying these analytes (GC/MS, HPLC-EC, and LC/MS)<sup>6-8</sup> there are few in which ACh, HA and their metabolites have been quantified simultaneously either in rodent brain microdialysate or in CSF matrices.<sup>9</sup> Reversed-phase (RP) liquid chromatography combined with MS detection is limited by method sensitivity due to potential co-elution with matrix-suppressing components and poor MS ionization under higher aqueous elution conditions.<sup>10</sup> Hydrophilic interaction liquid chromatography (HILIC) is increasingly becoming the technique of choice for these challenging polar analyte separations to improve chromatographic retention of polar species, orthogonal selectivity to reversed-phase chromatography for mixtures of polar and ionizable compounds, and increased mass spectrometry response.

The method described herein demonstrates the simultaneous quantification of ACh, HA, and their metabolites in human CSF in a 96-well format. This application uses a single-step sample preparation, dilution of a 20- $\mu$ L sample, followed by HILIC UPLC/MS/MS analysis. Using a sub-2- $\mu$ m particle size, the high efficiency CORTECS UPLC HILIC Column provided resolution from endogenous matrices, increased analyte sensitivity, and a short analysis time of 2.5 minutes, thereby resulting in a fast, sensitive, selective, and accurate method that meets the demands of high-throughput bioanalytical drug discovery.

## EXPERIMENTAL

### Sample preparation

20  $\mu\text{L}$  of artificial CSF (aCSF) standard, aCSF quality control (QC), or human CSF (containing 4 mM eSerine) QC samples were transferred to a 1-mL 96-well plate. 100  $\mu\text{L}$  of acetonitrile containing 1 ng/mL each of d4-acetylcholine, d4-histamine, d3-*tele*-methylhistamine, and d3-*tele*-methylimidazolacetic, which were used as internal standards (ISTD), was added to the samples. The plate was covered and vortexed. The samples were then centrifuged for five minutes at 4000 rpm, and 10  $\mu\text{L}$  of sample was analyzed by UPLC/MS/MS.

### UPLC conditions

System:	ACQUITY UPLC
Column:	CORTECS UPLC HILIC 1.6 $\mu\text{m}$ , 2.1 mm x 100 mm (p/n 186007106)
Mobile phase A:	100 mM ammonium formate, pH 3
Mobile phase B:	Acetonitrile
Gradient:	Start at 90% B, linear ramp to 60% B at 0.75 minute, hold for 0.25 minute, then ramp to 30% B in 0.25 minute, and hold for 0.65 minute. Return to initial conditions at 1.9 minutes.
Flow rate:	0.5 mL/min
Column temp.:	45 $^{\circ}\text{C}$
Sample temp.:	6 $^{\circ}\text{C}$
Injection volume:	10 $\mu\text{L}$
Run time:	2.5 minutes
Collection plates:	Waters <sup>®</sup> ACQUITY 1-mL collection plates

### MS conditions

Mass spectrometer:	Xevo TQ-S
Ionization mode:	ESI positive
Capillary voltage:	3.0 kV
Desolvation temp.:	550 $^{\circ}\text{C}$
Cone gas flow:	150 L/h
Desolvation gas flow:	900 L/h
Collision cell pressure:	3.58 X 10 <sup>(-3)</sup> mbar
Collision energy:	Optimized by component, see Table 1
Cone voltage:	Optimized by component, see Table 1

### Data management

Chromatography:	MassLynx <sup>®</sup> Software
Quantification:	TargetLynx <sup>™</sup> Software

## RESULTS AND DISCUSSION

### Mass spectrometry

Detection and quantification of ACh, HA, and their respective metabolites was achieved by ESI-MS/MS operating in the positive ion mode on a Waters Xevo TQ-S Mass Spectrometer. The multiple reaction monitoring (MRM) transitions chosen for ACh, HA, their respective metabolites, and corresponding deuterated stable isotope-labeled forms (used as Internal Standards) were automatically optimized using the MassLynx IntelliStart™ Software, as shown in Table 1. The short dwell times of 25 ms for each MRM transition, and fast scan time of the MS system allowed for the simultaneous acquisition of all compounds with  $\geq 10$  data points for each.

Compound	MRM transition	Cone voltage (V)	Collision energy (eV)
Acetylcholine	146.10 > 87.05	25	12
d4-Acetylcholine	150.20 > 91.30	30	15
Choline	104.20 > 60.10	30	15
Histamine	112.20 > 95.12	25	15
d4-Histamine	116.10 > 99.00	25	15
<i>tele</i> -Methylhistamine	126.10 > 109.20	25	12
d3- <i>tele</i> -Methylhistamine	128.80 > 112.20	25	12
<i>tele</i> -Methylimidazole acetic acid	141.09 > 95.05	25	12
d3 <i>tele</i> -Methylimidazole acetic acid	144.10 > 98.10	25	12

Table 1. MS conditions for ACh, Ch, HA, *t*-mHA, and *t*-MIAA, and their respective deuterated stable isotope-labeled ISTDs.

## UPLC separation

ACh, Ch, HA, t-mHA, and t-MIAA are highly polar, low molecular weight compounds present at relatively low concentrations, making them difficult to detect by standard reversed-phase (RP) chromatography. Additionally, quantitative analysis of these endogenous analytes in biological matrix is often difficult due to matrix-induced interferences and ion suppression from co-elution with related molecules, such as salts or other low molecular weight endogenous components.<sup>9</sup>

In this application, chromatographic separation of ACh, HA, and their respective metabolites was achieved utilizing a sub-2- $\mu\text{m}$  CORTECS UPLC HILIC Column on an ACQUITY UPLC System. The optimum ammonium formate concentration (mobile phase A) was determined to be 100 mM, pH 3, while mobile phase B consisted of acetonitrile. An optimum flow rate of 0.5 mL/min using a gradient from 90% to 30% B was employed with a cycle time of 2.5 minutes at a column temperature of 45 °C.

The mobile-phase additive concentration greatly influenced the specificity, sensitivity, and the ability to chromatographically resolve the analytes of interest from both mobile phase and endogenous matrix interferences. The higher buffer concentration of 100 mM (rather than 20 to 50 mM) greatly improved peak widths for the later eluting analytes. Specifically, peak tailing of t-MIAA was significantly reduced with the use of a high mM concentration of ammonium formate. Chromatographic retention and performance for the lower limit of quantification control (LLQC) samples of ACh, Ch, and their respective metabolites is shown in Figure 2. ACh, HA, their metabolites, as well as an isobar of ACh, Iso-ACh (3-carboxypropyl) trimethylammonium), eluted between 1.35 and 1.75 minutes, with peak widths less than 3.7 seconds at base.




Figure 2. Representative chromatograms of ACh, Ch, HA, t-mHA, and t-MIAA in aCSF at LLQC concentrations (16 pg/mL for ACh/t-mHA, 62 pg/mL for HA, 35 pg/mL for t-MIAA, and 140 pg/mL for Ch).

Iso-ACh ((3-carboxypropyl)trimethylammonium) was included in the analysis due to its presence at high concentrations in the brain, and it is reported to be a substrate in the production of g-betaine hydroxylase, an enzyme in the biosynthesis of carnitine.<sup>11</sup> Because ACh and Iso-ACh are isobaric, it is important to ensure chromatographic resolution for accurate quantification of ACh in CSF. An extracted human CSF sample (Figure 3) highlights the presence of a high endogenous concentration of Iso-ACh. ACh was spiked into human CSF at a concentration of 1000 pg/mL to demonstrate the chromatographic separation and concentration differences between ACh and Iso-ACh.




Figure 3. Representative chromatogram of ACh and Iso-ACh in human CSF (ACh overspike of 1000 pg/mL).

### Sample preparation

Artificial CSF (aCSF) was chosen as an alternative matrix to prepare standard curves to quantify all analytes. Use of aCSF as a surrogate matrix was a more practical alternative, since it was readily available and not as cost prohibitive as human CSF. Overspiked human CSF QC samples for ACh, HA, t-mHA, and aCSF QCs for Ch and t-MIAA were prepared to ensure aCSF was a suitable matrix for accurate quantification of all analytes. QC samples were prepared in aCSF for Ch and t-MIAA, since the endogenous basal levels were present in high ng/mL concentrations in human CSF, making quantification by standard addition difficult within the correct assay range for the other analytes measured. Additionally, since Ch was present in high ng/mL concentrations in human CSF, sample dilution with aCSF was required for accurate quantification within the dynamic range of the assay.

All human CSF QCs and human CSF samples contained a final concentration of 4 mM of the stabilizing agent eserine to prevent enzymatic conversion of ACh to Ch and acetate, as described by Zhang, Tingley, Tseng, *et al.* Standard curves, human CSF QCs, aCSF QCs, and samples were prepared in a 1-mL 96-well plate. A one-step sample dilution was performed with the addition of acetonitrile (1:5) containing the ISTDs described in the experimental section. The 96-well format allowed for sample preparation in <15 minutes, facilitating the high throughput of analysis required for discovery and development quantitative analysis.

### Linearity, precision, and accuracy

Deuterated stable isotope-labeled standards (ISTDs) for ACh, HA, t-mHA, and t-MIAA were used for quantitative analysis. The d4 ACh IS was used for Ch quantification. Standard curves (1/x weighting) for ACh, Ch, HA, t-mHA, and t-MIAA were linear (>0.99) across their quantitative dynamic range. Dynamic ranges, linearity, average QC accuracy, and lower limit of quantitation control (LLOQ) are shown in Table 2. A representative standard curve for ACh is shown in Figure 4.




Figure 4. Representative standard curve for ACh prepared in aCSF.

Compound	Dynamic range (pg/mL)	Linearity (1/x)	LLQC* (pg/mL)	Mean QC accuracy
Acetylcholine	10 to 10,000	0.998	16	102.2
Choline	100 to 30,000	0.999	140	103.3
Histamine	50 to 10,000	0.998	62	105.8
tele-Methylhistamine	10 to 10,000	0.999	16	102.2
tele-Methylimidazole acetic acid	20 to 30,000	0.999	35	97.6

\*LLQC: Lower Limit of Quantification Control

Table 2. Analytical performance of the UPLC/MS/MS assay for ACh, Ch, HA, t-mHA, and t-MIAA.

QC samples were prepared in pooled human CSF and aCSF to assess intra-sample precision and reproducibility. Basal levels of ACh, HA, and t-mHA were determined by analyzing un-spiked human CSF. The QC concentrations were then determined by subtracting average basal levels from the CSF source to provide the corresponding QC level. Representative results from overspiked human CSF QC samples for ACh, HA, and t-mHA analyses, as well as aCSF QC samples for Ch and t-MIAA analysis are shown in Tables 3 and 4. Following qualification of aCSF and human CSF calibrators, the endogenous basal concentrations of each analyte in human CSF were determined using the aCSF standard curves. A summary of all mean determined basal levels of ACh, Ch, HA, t-mHA, and t-MIAA is shown in Table 5. Accuracy and precision values met the FDA regulatory criteria for LC/MS/MS assays.<sup>12,13</sup>

ACh overspike concentration (pg/mL)	Final ACh QC concentration (pg/mL)	Mean (N=4) calculated ACh concentration (pg/mL)	SD	%CV	Mean (N=4) accuracy
16	20	21.7	0.5	2.4	108.5
125	130	133.7	6.9	5.1	102.8
1000	1004	1004.9	6.3	0.6	100.1
4000	4004	3893.1	75.7	1.9	97.2

HA overspike concentration (pg/mL)	Final HA QC concentration (pg/mL)	Mean (N=4) calculated HA concentration (pg/mL)	SD	%CV	Mean (N=4) accuracy
62	272	268.9	11.2	4.1	98.9
250	460	487.0	18.1	3.7	105.9
1000	1210	1377.1	40.3	2.9	113.8
4000	4210	4470.3	146.4	3.3	104.4

t-mHA overspike concentration (pg/mL)	t-mHA QC concentration (pg/mL)	Mean (N=4) calculated concentration (pg/mL)	SD	%CV	Mean (N=4) accuracy
16	577	592.9	14.9	2.5	102.8
250	811	848.3	11.3	1.3	104.6
1000	1561	1623.7	5.4	0.3	104.0
4000	4561	4447.8	55.0	1.2	97.5

Table 3. Representative ACh, HA, and t-mHA results from the analyses of QC samples prepared in human CSF.



t-MIAA aCSF QC concentration (ng/mL)	Mean (N=4) calculated t-MIAA concentration (ng/mL)	SD	%CV	Mean (N=4) accuracy
0.035	0.034	0.003	10.1	97.9
0.28	0.266	0.003	1.3	96.0
1.12	1.114	0.032	2.9	100.0
4.5	4.255	0.146	3.4	96.3

Ch aCSF QC concentration (ng/mL)	Mean (N=4) calculated Ch concentration (ng/mL)	SD	%CV	Mean (N=4) accuracy
0.14	0.149	0.009	6.1	105.0
0.56	0.571	0.025	4.3	103.6
2.15	2.182	0.061	2.8	100.7
9.00	9.063	0.175	1.9	103.8

Table 4. Representative t-MIAA and Ch results from the analyses of QC samples prepared in aCSF.

Compound	Mean (N=4) calculated concentration	Units	SD	%CV
ACh	4.1*	pg/mL	0.2	4.9
Ch	530.0**	ng/mL	16.1	3.0
HA	204.1	pg/mL	8.3	4.0
t-mHA	556.6	pg/mL	8.2	1.5
t-MIAA	20.5	ng/mL	0.0	0.1

\*Below the limit of quantification

\*\*Sample diluted 80X with aCSF

Table 5. Summary of measured mean endogenous basal levels in human CSF for ACh, Ch, HA, t-mHA, and t-MIAA, respectively.

## CONCLUSIONS

- A fast, simple, sensitive, and selective analytical scale UPLC method was developed for separation and simultaneous quantification of ACh, HA, and their metabolites in human CSF.
- The 96-well format allowed for sample preparation in <15 minutes, providing high throughput required for discovery and development analysis.
- Resolution and sensitivity of the CORTECS UPLC HILIC Column improved separation and resolution from endogenous matrix components allowing for analysis times of 2.5 minutes.
- The high sensitivity of the Xevo TQ-S MS facilitated the use of small sample volumes (20 µL) and a 5X dilution to achieve detection limits as low as 10 pg/mL with a broad quantitative dynamic range of 10 to 30,000 pg/mL.
- QC samples for all analytes easily passed FDA regulatory criteria, with % CVs of 0.3% to 10.1%, and an accuracy range of 94.7% to 113.7% for all analytes tested, indicating a very reproducible and accurate method.
- The method described herein shows promise for highly selective and sensitive quantification of multiple neurological biomarkers in the discovery and developmental stages of pharmaceutical drug development.

## References

1. Jia JP, *et al.* Differential acetylcholine and choline concentrations in the cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. *Chin Med J (Engl)*. 2004; 117(8): 1161-4.
2. Vohora D, Bhowmik M. Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuse. *Front Syst Neurosci*. 2012; 6: 72.
3. Jadidi-Niaragh F, Mirshafiey A. Histamine and histamine receptors in pathogenesis and treatment of multiple sclerosis. *Neuropharmacology*. 2010; 59(3): 180-9.
4. Ito C. The role of the central histaminergic system on schizophrenia. *Drug News Perspect*. 2004; 17(6): 383-7.
5. Alvarez EO. The role of histamine on cognition. *Behav Brain Res*. 2009; 199(2): 183-9.
6. Prell GD, Green JP. Measurement of histamine metabolites in brain and cerebrospinal fluid provides insights into histaminergic activity. *Agents Actions*. 1994; 41: C5-8.
7. Huang T, *et al.* Detection of basal acetylcholine in rat brain microdialysate. *J Chromatogr B Biomed Appl*. 1995; 670(2): 323-7.
8. Bourgoigne E, *et al.* Simultaneous quantitation of histamine and its major metabolite 1-methylhistamine in brain dialysates by using precolumn derivatization prior to HILIC-MS/MS analysis. *Anal Bioanal Chem*. 2012; 402(1): 449-59.
9. Zhang Y, *et al.* Development and validation of a sample stabilization strategy and a UPLC-MS/MS method for the simultaneous quantitation of acetylcholine (ACh), histamine (HA), and its metabolites in rat cerebrospinal fluid (CSF). *J Chromatogr B Analyt Technol Biomed Life Sci*. 2011; 879(22): 2023-33.
10. Grumbach ES, Diehl DM, Neue UD. The application of novel 1.7 microm ethylene bridged hybrid particles for hydrophilic interaction chromatography. *J Sep Sci*. 2008; 31(9): 1511-8.
11. Zhu Y, *et al.* In vivo microdialysis and reverse phase ion pair liquid chromatography/tandem mass spectrometry for the determination and identification of acetylcholine and related compounds in rat brain. *Rapid Commun Mass Spectrom*. 2000; 14(18): 1695-700.
12. Viswanathan CT, *et al.* Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. *Pharm Res*. 2007; 24(10): 1962-73.
13. Bansal S, DeStefano A. Key elements of bioanalytical method validation for small molecules. *AAPS J*. 2007; 9(1): E109-14.

\* To watch summaries of other application notes, visit: [www.waters.com/MTS](http://www.waters.com/MTS)

# Waters

THE SCIENCE OF WHAT'S POSSIBLE.®

Waters, The Science of What's Possible, ACQUITY, UPLC, Xevo, ACQUITY UPLC, and MassLynx are registered trademarks of Waters Corporation. CORTECS, TargetLynx, and IntelliStart are trademarks of Waters Corporation. All other trademarks are the property of their respective owners.

©2013 Waters Corporation. Produced in the U.S.A.  
October 2013 720004722EN LM-PDF

**Waters Corporation**  
34 Maple Street  
Milford, MA 01757 U.S.A.  
T: 1 508 478 2000  
F: 1 508 872 1990  
[www.waters.com](http://www.waters.com)

